Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD)

Inclusion Criteria: * Males and non-pregnant females, age 18 - 60 years old * Subject meets DSM-5 criteria for OUD and/or other SUDs including alcohol (assessed via the SCID-5) of at least two years duration * Subject is currently receiving outpatient treatment from the WVU Comprehensive Opioid Addiction Treatment Program (COAT), Intensive Outpatient Program (IOP) or any other program which implements the COAT model; residential or inpatient treatment from the WVU Center for Hope and Healing or an affiliated WVU hospital; or receiving outpatient/inpatient/residential treatment from similar programs that are well known to the research team. If the subject is prescribed medication for AUD or OUD (e.g. buprenorphine-naloxone, naltrexone), they will be on a stable dose of the medication for the 7 days prior to the procedure. Stable is defined as within the therapeutic range but does not require same exact dose for 7 days. * Subject has been off opioids and other illicit substances, except for cannabis, confirmed via urine toxicology screen * The NAc is apparent on MRI such that treatment targeting can be performed directly (visible on MRI) and indirectly (using other anatomical structures for measurements) * Subject is able to communicate sensations during the Exablate Transcranial procedure * Subject is willing to cooperate with the study requirements including compliance with the regimen and completion of all study visits * Subject is able to make own medical decisions as dete…